本院現有抗癌藥品一覽表

Size: px

Start display at page:

Download "本院現有抗癌藥品一覽表"

庸诚蒋
7 years ago
Views:

1 本院現有抗癌藥品作用及副作用ㄧ覽表 No. 藥品代號 Trade name (Generic name) (Potency) I. Alkylating Agents 1 20B021 Myleran (Busulfan) 2 mg/tab 2 20C052 Leukeran (Chlorambucil) 2 mg/tab 3 20A016 Alkeran (melphalan) 2 mg/tab 4 10M079 Alkeran (melphalan) 50 mg/vial 5 20E014 Endoxan (Cyclophosphamide) 50 mg/tab 6 10C164 Endoxan (Cyclophosphamide) 200 mg/10ml/vial 7 10D018 DTIC (Dacarbazine) 200 mg/20ml/vial 8 10I013 Holoxan (Ifosfamide) 2 gm/50ml/vial II. Antimetabolites 9 20T051 UFUR (tegafur 100mg + uracil 224mg)/cap 10 10F149 5Fu (Fluorouracil) 1000 mg/10 ml/amp 廠牌 GSK Glaxo 最大劑量 Max. dose Maintenance not exceed 0.1 mg/kg/d 48 mg/day or 60 ug/kg /day 常用劑量 Usual dose 24 mg/day for 36 weeks Induction remission: mg/kg/d for 36 weeks; Intermittently: 0.4 mg/kg every 24 weeks. WELLCOM 6 mg/day for 23 weeks 和 discontinued for up to 4 weeks, afetr which a maintenance dose of 2 mg/day may be instituted. GSK 晚期神經母細胞瘤使用異體骨髓移植 mg/m2 ( 分三天 ) 單用或合併 RT / cytotoxic drugs Orion Oral: mg/ m 2 /day over 4 5 days IV: mg/ m 2 every 2128 days. (or mg/ m 2 ) Baxter Hospira 24.5 mg/kg/day for a period of 10 days, repeated every 46 weeks. Or mg/ m 2 on day 1 through 5, every 34 wks. 16 g/m 2 /cycly 1.2 gm/ m 2 /day for 5 consecutive days every 3 百特 weeks. 慢性骨髓性白血病. 適應症 Indication 多發性骨髓瘤, 淋巴瘤, 慢性淋巴性白血病. 多發性骨髓瘤緩解療法, 無法切除的卵巢癌. 多發性骨髓瘤, 卵巢癌, 小兒神經母細胞瘤 ( 骨髓移植 high dose) 大腸直腸癌, 子宮頸癌, Wilm s tumors, 肺癌, 乳癌, 卵巢癌, 各種白血病, nonhodgkin s lymphoma, 神經母細胞瘤, retinoblastoma, 膀胱癌, Hodgkin s disease, 多發性骨髓瘤, 軟組織肉瘤轉移性黑色素瘤, 腎臟癌, 軟組織或骨組織或骨肉瘤, 固態瘤, 淋巴瘤 Germ cell testicular, 頭頸癌, 乳癌, 子宮頸癌, 卵巢癌, 軟組織肉瘤, ewing s sarcoma, osteosarcoma, Hodgkin s 和 nonhodgkin s 淋巴瘤, 非小細胞肺癌, 急性淋巴性白血病, 和神經母細胞瘤. 修正日期 : 藥劑部製副作用 ADR 骨髓抑制, 痙攣, 靜脈栓塞, 間質肺炎, 出血性膀胱炎, 永久性禿頭使用高劑量時. 骨髓抑制, 肝毒性, 肺纖維化, 肺支氣管再生不良, 不孕, 周邊神經病變, 皮膚反應, 胃腸不適. 白血球缺乏症, 血小板缺乏症, 肺纖維化和肺部浸潤, 無月經, 禿頭, 不孕, 抗利尿激素不正常分泌, 噁心, 嘔吐, 口腔潰爛常見 : 禿頭, 口腔炎嚴重的 : 血管炎, 溶血性貧血, 骨髓抑制 ( 常見 ), 肝炎, 黃疸, 肝指數異常, 過敏反應 ( 罕見的 ), 不孕症, 肺纖維化, 肺浸潤白血病, 心肌病變, 心肌壞死, 頭暈, 抗利尿激素不正常分泌, 噁心, 嘔吐, 胰臟炎, 膀胱炎, 出血性膀胱炎, 性功能障礙, 肝毒性, 視力模糊, 間質肺炎, 肺纖維化, 禿頭, 外滲造成蜂窩性組織炎, 過敏噁心和嘔吐, 白血球缺乏症和血小板缺乏症, 致死性肝靜脈栓塞, 腦出血, 姿勢性低血壓, 虛弱, 神經病變, 視力模糊, 頭痛, 類感冒症狀, 痙攣, 厭食, 肝毒性, 禿頭, 過敏骨髓抑制, 出血性膀胱炎, 中樞神經毒性, 噁心和嘔吐. 東洋 Tegafur: 300 mg/m 2 /day 分成三次胃癌, 大腸直腸癌噁心, 嘔吐, 口炎, 腹瀉, 皮膚紅疹, 和神經毒性 ( 頭暈, 運動失調 ) 南光 12 mg/kg/day IV for 4 days. If no toxicity occurs, 6 mg/kg IV is given on days 6,8,10 和 12. 大腸, 直腸癌, 乳癌, 胃癌, 胰臟癌血液惡質症, 心臟毒性, 噁心, 嘔吐, 厭食, 腹瀉, 丘狀紅疹.

2 11 20M060 6MP (6Mercaptopurine) 50 mg/tab 12 20C044 Xeloda (Capecitabine) 500 mg/tab 13 AraC (Cytarabine) 10C095 (100 mg1ml//vial) 10C087 (500 mg/5ml/vial) 14 20M010 M.T.X (Methotrexate) 2.5 mg/tab 15 10M106 M.T.X (Methotrexate) 500 mg/20ml/vial 16 10F054 Fludara (Fludarabine) 50 mg/vial ORION Induction therapy of ALL: 2.55 mg/kg/day for adults 和 children. Maintenance therapy: mg/kg/day. Roche 2500 mg/ m 2 /day in two divided dose for two weeks with a 1week rest period. PFIZER/ Pharmacia ORION 景泰代理 BAXTER 急性淋巴性白血病. 使用 paclitaxel 和 anthracycline 無效之轉移性乳癌, 大腸直腸癌 mg m 2 /day for 57 days. 慢性骨髓性白血病, 淋巴性白血病, 急性淋巴性白血病, 急性非淋巴性白血病, 和 meningeal 白血病 mg/day or 1215 mg/ m 2 /dose as a 4h infusion; oral dose are 1530 mg/day as a single dose; intrathecal dose are 612 mg/week. IV, 25 mg/m2/day x 5 days, repeat every 28 days. 乳癌, 急性淋巴性白血病, 頭頸癌, 卵巢癌, nonhodgkin s lymphoma, 骨肉瘤, 大腸直腸癌, Hodgkin s lymphoma. 使用一種以上含 alkylatingagent 的化療治療無效之 Bcell 慢性淋巴性白血病劑量相關的骨髓抑制 ; 肝毒性 ( 劑量大於 2.5 mg/kg/day); 免疫抑制 ; 出血, 手口足症, 腹瀉, 噁心, 嘔吐, 水腫, 口炎. 骨髓抑制, 神經病變, 胃腸不適, 肝毒性, 過敏. 白血球缺乏症, 血小板缺乏症, 貧血, 泛血球缺乏症, 血管炎, 神經毒性, 頭痛, 發燒, 痙攣, 運動失調, 嗜睡, 厭食, 噁心和嘔吐, 腹瀉, 口炎, 偽膜性腸炎, 腎毒性, 膀胱炎, 月經失調, 不孕, 肝毒性, 肝毒性, 視力模糊, 間質肺炎, 禿頭, 紅疹, 光毒性, SLE, 過敏常見 : 顫抖, 食慾變差, 噁心, 嘔吐, 無力, 疲倦嚴重的 : 水腫 ( 常見 ), 皮膚發育不全 ( 罕見的 ), 自體免疫之溶血性貧血, GVHD 使用未經放射線照射之血液造成 ( 罕見的 ), 骨髓抑制 ( 常見 ), 神經毒性, 肺炎 ( 常見 ), 發燒 ( 常見 ), 感染 17 10G019 Gemzar (Gemcitabine) 200 mg/5ml/vial 18 10P070 Alimta (Pemetrexed) 500 mg/20ml/vial 10P123 Alimta (Pemetrexed) 100 mg/vial Lilly 1000 mg/m 2 once a week for up to 7 weeks. 胰臟癌和非小細胞肺癌, 晚期乳癌和卵巢癌. 骨髓抑制 (doselimiting), 類感冒症狀 (occasionally doselimiting), 疲倦, 發燒, 週邊水腫, 蛋白尿, 皮膚的反應, 胃腸道副作用. Lilly Max. 600 mg/m2 1. Malignant mesothelioma of pleura: 500 mg/m2 IV over 10 minutes on day 1, followed 30 minutes later by cisplatin 75 mg/m2 infused IV over 2 hours; repeat cycle every 21days 2. 非小細胞肺癌 : 500 mg/m2 IV over 10 minutes on day 1 of each 21day cycle 常見 : 食慾變差, 噁心, 嘔吐, 疲倦嚴重的 : 皮膚脫屑 ( 常見 ), 皮膚紅疹 ( 常見 ), 顫抖, 腹瀉 ( 常見 ), 口腔炎 ( 常見 ), 貧血, 白血球減少, 嗜中性球減少血小板減少症 ( 常見 ), 咽喉炎 ( 常見 ), 發燒, 感染 ( 常見 ) 19 10A102 Vidaza (Azacitidine ) 100mg/vial PHARMION 75 mg/m(2) SUBQ or IV daily for 7 days, may increase dose to 100 mg/m(2) if no improvement seen after 2 cycles and the only toxicity is nausea and vomiting Myelodysplastic syndrome, Refractory anemia, refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia 常見 : Chest pain,erythema, Injection site reaction, Petechiae, Pruritus, Constipation, Diarrhea, Loss of appetite, Nausea, Vomiting, Hematologic: Anemia, Ecchymosis, Leukopenia, Neutropenia, Thrombocytopenia, Arthralgia, Dizziness, Headache, Insomnia, Lethargy, Dyspnea, Nasopharyngitis, Pneumonia, Upper respiratory infection, Fatigue, Fever III. Antitumor antibiotics 20 10B064 BLEO (Bleomycin) 15 mg/3ml/vial 21 10M087 Mitomycin C 10 mg/vial 日本化藥 >400 U cumulative total may cause 肺部毒性 1020 unit/ m 2 /week or twice weekly. 睪丸癌, Hodgkin s lymphoma, nonhodgkin s lymphoma, 麟狀上皮細胞癌如 : 頭頸癌, 陰莖, 子宮頸, 和陰道癌 ;. 腹膜積水之硬化劑. Kyowa 1. Single dose: 20 mg/m 2 IV 每 6 to 8 weeks mg/m 2 /day IV for 5 days 胃癌或胰臟癌, 乳癌, 頭頸癌, 子宮頸, 肺, 大腸直腸和膽管癌, 膀胱癌肺部毒性 ( 劑量限制毒性 ), 嚴重特異體質反應 (1%) 骨髓抑制, 噁心, 嘔吐, 腎毒性, 間質性肺炎, 禿頭

3 22 10D103 COSMEGEN (Dactinomycin) 0.5 mg/vial 23 10D084 Adriblastina (Doxorubicin) 10 mg/vial 24 10D092 Lipodox liposome (Doxorubicin liposome) 10 mg/10 ml/vial 25 10E065 Pharmorubicin (Epirubicin) 10 mg/5ml/vial 26 10I063 Zavedos (Idarubicin) 5 mg/5ml/vial 27 10I190 Ixempra (Ixabepilone) 15mg/vial MSD PFIZER mg/m 2 ; 2. 若病人曾接受過胸部放療或併用 cyclophosphamide: 450 mg/m 2 睪丸癌 : 1000 mcg/m(2) IV day 1 in combination with chemotherapy Nephroblastoma: 15 mcg/kg IV every day for 5 days (in combination with other chemotherapy) 小兒癌睪丸癌 Kaposi's sarcoma Nephroblastoma 6075 mg/m 2 每三週ㄧ次急性白血病, 膀胱癌, 乳癌, 肝癌, Hodgkin's disease, 神經母細胞瘤, nonhodgkin's lymphoma, 攝護腺癌, 肉瘤, 甲狀腺癌, 肺癌, 和 Wilms' tumor. 臺灣東洋 AIDSrelated Kaposi's sarcoma: 20 mg/m 2 IV 每三週ㄧ次 Refractory 卵巢癌 : 50 mg/m 2 每 4 週ㄧ次 AIDSrelated Kaposi's sarcoma, 頑固性卵巢癌骨髓抑制, 口炎, 噁心, 嘔吐, 厭食, 紅疹, 禿頭, 痤瘡, 肝炎心臟毒性, 骨髓抑制, 可逆性的禿頭, 急性噁心嘔吐, 局部組織蜂窩炎. 骨髓抑制, 口炎, 噁心, 嘔吐, 厭食, 紅疹, 禿頭法瑪西亞普強 Max cumulative mg/ m 2 repeated every 34 weeks. 淋巴結轉移之乳癌開刀後之輔助治療. 骨髓抑制 ( 白血球缺乏症 ); 噁心, 嘔吐, 口炎, 禿頭 ; 缺血 dose: 900 mg/ m 2 性心衰竭 (35% with 累積劑量 1000 to 1600 mg/ m 2 ) PFIZER 150 mg/m 2 12 mg/ m 2 /day in combination with cytarabine for 3 days. Bristol 40 mg/m(2) IV over 3 hours every 3 weeks Breast cancer, Locally advanced or metastatic, as monotherapy in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and ca pecitabine 急性非淋巴性白血病和急性淋巴性白血病. 骨髓抑制, 特別是白血球缺乏症, 噁心, 嘔吐, 禿頭, 口炎 ; 缺血性心衰竭, 肝功能異常. 常見 : Alopecia, Handfoot syndrome due to cytotoxic therapy), Nail changes, Abdominal pain, Constipation, Diarrhea, Inflammatory disease of mucous membrane, Loss of appetite, Nausea, Stomatitis, Vomiting, Arthralgia, Musculoskeletal pain, Myalgia, Asthenia, Peripheral neuropathy, Fatigue IV. Epitodophyllotoxins 28 Vepesid (VP16) (Etoposide) 10E mg/5 ml/vial 20E022 50mg/cap FRESENIU S KABI BRISTOL mg/ m 2 /day for 35 ddays, repeated at 34 week intervals. 小細胞肺癌, 睪丸癌, 急性非淋巴性白血病, 和淋巴白血球缺乏症 (doselimiting factor), 血小板缺乏症 ; 噁心嘔瘤 ; 頑固型兒癌, 肝癌, 卵巢癌, 白血病, 和非小細胞吐 ; 缺血性心衰竭, 心肌梗塞, 低血壓 ( with rapid IV 肺癌 infusion), 周邊神經病變, 厭食, 口炎, 卵巢失去功能, 肝炎, 可逆性的禿頭, 和過敏反應. V. Antimitotic 29 10V056 Velbe (Vinblastine) 10 mg/10 ml/vial 30 10O023 Oncovin (Vincristin) 1 mg/1 ml/vial HOSPIRA HOSPIRA 18.5 mg/ m 2 /wk 412 mg/ m 2 or 1.52 mg/ m 2 /day for 5 days. 轉移性睪丸癌 ; 淋巴瘤 ex. Hodgkin s disease, Kaposis sarcoma, 乳癌, mycosis fungoids, choriocarcinoma, 和 LettererSiwe disease. 2 mg/each dose Children: 2mg/ m 2 at weekly interval. Adult: 1.4 mg/m 2 with a duration ranging from 48 weeks. 孩急性淋巴性白血病之誘導治療 ; Hodgkin s disease, Wilm s tumor, 小細胞肺癌, nonhodgkin s lymphoma, malignant thyoma, Kaposi s sarcoma, osteogenic sarcoma, malignant pheochromocytoma, 和其他癌症. 白血球缺乏症和血小板缺乏症, 噁心嘔吐, 口腔粘膜炎, 抗利尿激素不正常分泌, 缺血性心臟毒性, 掉髮, 皮膚炎, 神經毒性神經毒性, 神經疼痛, 肌肉無力, 白血球缺乏症, 血小板缺乏症. 便祕, 噁心和嘔吐, 複視, 禿頭 31 10V022 Navelbine (Vinorelbine) 10 mg/1 ml/vial PIERRE FABRE 30 mg/ m 2 weekly 晚期乳癌, 非小細胞肺癌, nonhodgkin s lymphoma, Hodgkin s disease, 和卵巢癌. 白血球缺乏症, 貧血和血小板缺乏症, 神經毒性 ( 比其他的 vinca alkaloid 少 ), 噁心嘔吐, 腹瀉, 口炎, 禿頭和過敏反應. 20V021 Navelbine (Vinorelbine) 20 mg/cap SCHERER GMBH 120~160 mg/wk. 1 st,2 nd,3 th wk: 60mg/m 2 /wk. Max. 120 mg/wk. 4 th ~: 80mg/m 2 /wk, Max. 160 mg/wk.

4 32 10D076 Taxotere (Docetaxel) 20 mg/0.5 ml/vial 33 Phyxol (Paclitaxel) 10P mg/15 ml/vial 10P mg/vial 34 10C241 Jevtana (Cabazitaxel) 60mg/1.5 ml Sonofi aventis mg/m 2 every 3 weeks. 使用其他化療藥無效之晚期或轉移性乳癌 ; 卵巢癌和非小細胞肺癌杏輝 mg/ m 2 every 3 weeks. 卵巢癌, 乳癌, 非小細胞肺癌, 和 AIDSrelated Kaposi s sarcoma; 急性白血病, 黑色素細胞瘤, 和其他癌症 Aventis 25 mg/m(2) IV over 1 hour every 3 weeks Hormone refractory prostate cancer, Metastatic, in combination with prednisone, after failure of a prior docetaxelcontaining regimen 白血球缺乏症 (doselimiting), 過敏反應 ( ~60%), 無力, 噁心, 嘔吐, 腹瀉, 禿頭, 感覺神經異常 ; 口腔粘膜炎白血球缺乏症 (doselimiting), 過敏, 口腔粘膜炎, 禿頭, 神經病變, 肌痛, 關節痛, 胃腸不適, 心律不整. 常見 : Alopecia, Constipation, Diarrhea, Loss of appetite, Nausea, Vomiting, Anemia, Leukopenia, Neutropenia, Thrombocytopenia, Backache, Asthenia, Peripheral neuropathy, Hematuria, Cough, Dyspnea, Fatigue, Fever VI. Topoisomerase Inhibitors 34 10T028 Hycamtin (Topotecan) 4 mg/4ml/vial 35 10I097 Campto (Irinotecan) 100 mg/5ml/vial VII.Hormones 36 17L078 Leuplin depo (Leuprorelin acetate) 3.75 mg/vial 37 17L078 Lupron (Leuproline Acetate) 5 mg/2.8 ml/vial 38 17L121 Leuplin Depot 3M Inj (Leuproline Acetate) mg/syring 39 27C074 Anrocur (Cyproterone Acetate) 50 mg/tab 40 20B047 BicalutamideTeva (Bicalutamide) 50 mg/tab 41 20T019 Nolvadex (Tamoxifen Citrate) 10 mg/tab 42 20E030 Estracy (Estramustine) 140 mg/cap GLAXO 1.5 mg/ m 2 /day for 5 days every 3 weeks. 頑固性小細胞肺癌或轉移性卵巢癌之第二線治療藥白血球缺乏症, 血小板缺乏症, 貧血, 禿頭, 噁心嘔吐, 腹物 ; 對非小細胞肺癌, 攝護腺癌和大腸直腸癌也有瀉, 口腔粘膜炎, 頭痛, 疲倦, 紅疹, 肝酵素異常, 蛋白尿效. PFIZER TAKEDA GRUNENTHAL GmbH solid tumor: mg/ m 2 /wk for 4 wks. Advance: 500 mg/ m mg/ m 2 weekly for 4 weeks followed by a rest period of 2 weeks. 肺癌, 大腸直腸癌, 卵巢癌, 和 nonhodgkin s lymphoma. 白血球缺乏症, 腹瀉, 疲倦, 肝功能異常, 禿頭, 皮膚紅疹, 1 mg SC daily, or in the depot formulation 7.5 IM 晚期攝護腺癌熱潮紅 ; 水腫, 骨頭痛, 血栓, 胃腸不適. monthly, mg every 3 months, or 30 mg every 4 months. TAKEDA mg SC once every 3 months. Schering mg/day 晚期攝護腺癌陽萎, 頭痛, 月經失調, 男性女乳症, 體正增加, 血脂異常, 胃腸不適, 貧血 ; 肝毒性 TEVA AstraZeneca Pharmacy 50 mg QD 晚期攝護腺癌熱潮紅, 乳房腫脹, 男性女乳症, 疼痛, 無力, 便祕 1020 mg bid 乳癌熱潮紅, 噁心和 / 或嘔吐, 陰道出血, 月經失調, 皮膚紅疹, 眼睛副作用 ( 角膜病變, 白內障, 視網膜病變 ), 肝毒性. 14 mg/kg/day 分 34 次晚期攝護腺癌血小板缺乏症, 白血球缺乏症, 心血管副作用 ( 缺血性心臟病, 靜脈栓塞, 血栓靜脈炎 ), 男性女乳症, 噁心, 嘔吐, 肝毒性, 蕁麻疹

5 43 20E038 Aromasin (Exemestane) 25 mg/tab 44 20L021 Femara (Letrozol) 2.5 mg/tab 45 20A032 Ansuzole (Anastrozole) 1 mg/tab 46 10F115 Faslodex (Fulvestrant) 250 mg/5ml/amp 47 27M074 Farlutal (Medroxyprogesterone) 500 mg/tab VIII. Platinum 48 Paraplatin (Carboplatin) 450 mg/45ml/vial 49 ABIPLATIN (Cisplatin) PFIZER 25 mg QD 乳癌頭暈, 頭痛, 疲倦, 失眠, 熱潮紅, 噁心, 嘔吐, HDL 下降諾華 2.5 mg QD 晚期乳癌肌肉骨骼副作用 (ie 肌肉疼痛, 骨骼疼痛, 背痛 ), 噁心, 嘔吐, 頭痛, 疲倦. 胸部疼痛, 便祕, 腹瀉, 腹痛, 熱潮紅美時 AstraZeneca Pfizer FRESENIUS KABI FRESENIUS KABI 1.0 mg QD 停經後雌激素接受器為陽性或不清楚之局部晚期或轉移性乳癌第一線治療 250 mg IM once monthly 雌激素受體陽性的停經後婦女, 已接受過荷爾蒙療法後疾病復發或惡化的之局部晚期或轉移性乳癌乳癌 : 1 gm/day Other cancer: mg/day 子宮內膜癌, 腎臟癌, 乳癌, 攝護腺癌之緩和療法肌肉骨骼副作用 (ie 肌肉疼痛, 骨骼疼痛, 背痛 ), 無力, 噁心, 嘔吐, 頭痛, 嗜睡, 疲倦, 便祕, 腹瀉, 熱潮紅, 發疹背痛, 噁心, 嘔吐, 頭痛, 嗜睡, 疲倦, 便祕, 腹瀉, 腹痛, 貧血, 注射部位疼痛發炎月經不規則, 腹痛或脹痛 t, 體重減輕, 頭暈, 頭痛, 無力, 和神經緊張 360 mg/ m 2 once every 4 weeks. 卵巢癌, 頭頸癌, 小細胞肺癌. 骨髓抑制 ( 血小板缺乏症, 白血球缺乏症 ), 噁心和嘔吐 mg/ m 2 once every 34 weeks or 5 days each cycle. 睪丸癌, 卵巢癌, 膀胱癌, 非小細胞肺癌, 子宮頸癌, 骨癌, 頭頸癌. 神經毒性, 腎毒性, 耳毒性, 嚴重噁心嘔吐. 腎毒性 10P020 Platinol (Cisplatin) 10mg/20ml/via 50 10O031 Oxaliplatin (Eloxatin) 50 mg/vial IX. Anthracenedione 51 10M053 Novantrone (Mitoxantrone) 20 mg/10 ml SANOFI AVENTIS 景德 Cumulated dose>800 mg/m2( 6 course) Single agent: 37 mg/ m 2 Combination with taxotere: 14 mg/ m mg/m 2 晚期大腸直腸癌周邊感覺神經病變 (doselimiting toxicity), 白血球缺乏症, 噁心, 嘔吐, 和腹瀉. 12 mg/ m 2 on day 13. 急性白血病, 攝護腺癌. 白血球缺乏症, 血小板缺乏症, 心臟毒性, 胃腸道毒性, 肝毒性, 皮膚反應. X. Biological response modifiers 52 10I124 Proleukin (Interleukin2) 18 MIU/vial CHIRON Metastatic renal cell carcinoma 和黑色素瘤 : 600,000 units/kg Q 8H by a 15minute intravenous infusion for a maximum of 14 doses; followed by 9 days of rest, then repeat schedule for another 14 doses; maximum of 28 doses per course. 腎癌, 轉移性黑色素細胞瘤低血壓, 類感冒症狀, 腎功能變差, 呼吸急促 XI. Monoclonal antibodies 53 10B080 Avastin Bevacizumab 100 mg/4 ml/vial Roche 5 mg/kg in 100 ml N/S IV infusion ( 初用 >90min, 若可耐受, 輸注時間可縮短為 60 min 30 min) every 14 days until disease progression is detected 與 5FU 併用, 治療轉移性大腸直腸癌第一線藥物常見 : 無力, 腹痛, 頭痛, 深層靜脈栓塞, 血小板減少症, 高血壓, 腹瀉, 噁心, 嘔吐, 食慾不振, 口腔炎, 便秘, 上呼吸道感染, 流鼻血, 呼吸困難, 剝落性皮膚炎, 蛋白尿. 嚴重 : 胃腸道穿孔, 傷口癒合困難, 嚴重出血, 嚴重高血壓, 腎症候群, 動脈栓塞, 心衰竭

6 54 10C225 Erbitux Cetuximab 5 mg/ml, 20 ml/vial Merck 400 mg/m2 initial IV loading dose over 120 min, followed by weekly doses of 250 mg/m2 IV over 60 min 頭頸癌常見 : 低血鎂 (10% to 50%), 便秘, 腹瀉, 噁心嚴重的 : 皮膚紅疹, 青春痘 (1%), 貧血, 白血球減少 ( 常見 ), 輸注相關不良反應 (3%), 腎衰竭 (2%), 間質性肺炎 (0.5%), 肺栓塞 (1%), 發燒 (5%), 敗血症 (3%) 55 Mabthera (Rituximab) 10R008 (100 mg/10 ml/vial) 10R024 (500 mg/50 mg/vial) Roche 375 mg/m 2 IV infusion once weekly for 4 or 8 doses Elapsed or refractory lowgrade or follicular, CD20 positive, B cell nonhodgkin's lymphoma. 輸注相關的反應, 腫瘤裂解症狀, 嚴重的皮膚反應, 腹痛, 貧血, 呼吸急促, 低血壓, 白血球缺乏症, 寒顫, 發燒, 頭痛, 噁心, 嘔吐, 血管水腫, 低血壓 T052 Herceptin (Trastuzumab) 440 mg/vial 57 10A083 Mabcampath (Alemtuzumab) 30 mg/ml/vial 58 10P157 Pertuzumab (PERJETA) 420mg/14ml Roche Initial loading dose: 4 mg/kg over 90minutes, followed by weekly infusions of 2 mg/kg IV infused over 30minutes. Bayer HER2 蛋白質過度表現之乳癌 Initiate therapy at 3 mg as a 2hour IV infusion daily; when the 3mg daily dose is tolerated (e.g., Chronic Lymphocytic Leukemia; CLL infusionrelated toxicities are Grade 2 or less), escalate to 10 mg daily and continue until infusionrelated toxicities are grade 2 or less; when the 10mg dose is tolerated, the maintenance dose (30 mg per day, 3 times per week on alternate days) may be initiated; total duration of therapy, including dose escalation, is 12 weeks Roche 840 mg IV over 60 minutes (initial dose), then 420 Breast cancer mg IV over 30 to 60 minutes every 3 weeks for 3 to 6 cycle 疼痛, 無力, 發燒, 寒顫, 噁心 / 腹瀉,, 缺血性心衰竭發燒, 寒顫, 噁心, 嘔吐, 輸注相關的反應, 血小板缺乏症, 白血球缺乏症常見 : Alopecia, Rash, Decrease in appetite, Diarrhea, Inflammatory disease of mucous membrane, Nausea, Vomiting, Anemia,, Neutropenia, Asthenia, Headache, Peripheral neuropathy, Fatigue XII. Cytoprotective agents 59 10M061 Uromitexan (mesna) 400 mg/4 ml/amp XIII. Protein kinase inhibitors 60 20I046 Glivec (Imatinib mesylate) 100 mg/cap 61 20G018 Iressa (Gefitinib) 250 mg/tab 百特 1. 60% ifosfamidedose: 20% of the ifosfamide dose (w/w) at 0,4,8 hr of ifosfamide dose % ifosfamide dose Norvatis 1. CML: chronic phase 400 mg/day, accelerated/blast crisis phase 600 mg. 2. metastatic gastrointestinal stromal tumors (GIST) :400 or 600 mg/day. Prophylactic agent to reduce the incidence of ifosfamideinduced 出血性膀胱炎 Philadelphia positive 慢性骨髓性白血病 (CML), 胃腸基底細胞瘤 (GIST) Astrazeneca 250 mg QD Monotherapy in patients with locally 晚期 / 轉移性非小細胞肺癌 as thirdline therapy, after failure of both platinumbased 和 docetaxel therapies 高血壓, 噁心, 嘔吐, 腹瀉, 腎毒性, 過敏血小板缺乏症, 白血球缺乏症, 肝指數上升, 水腫, 肌痙攣, 噁心, 腹瀉. 腹瀉 (48%), 紅疹 (43%), 青春痘 (25%), 皮膚乾燥 (13%), 噁心 (13%), 嘔吐 (12%), 間質性肺疾病 (< 1%) E048 Tarceva (Erlotinib) 150 mg/tab 20S020 Nexavar Sorafenib 200 mg/tab Roch Bayer 150 mg QD Monotherapy in patients with locally 晚期 / 轉移性非小細胞肺癌 as thirdline therapy, after failure of both platinumbased 和 docetaxel therapies 400 mg BID Liver carcinoma 晚期腎癌 (renal cell carcinoma) 腹瀉 (48%), 紅疹 (43%), 青春痘 (25%), 皮膚乾燥 (13%), 噁心 (33%), 嘔吐 (23%), 間質性肺疾病 (< 1%) 高血壓 (17% ), 手足症 (30% ), Pruritus (19% ), 紅疹 (40% ) 噁心 (23% ), 嘔吐 (16% ) 貧血 (44% ), Lymphocytopenia (23% ), Neutropenia (18% )

7 64 20S038 Sutent (Sunitinib) 12.5 mg/cap 65 10T113 Temsirolimus (Torisel) 25mg/ml/vial. 輝瑞 Pierre Fabre Medicament Production 50 mg QD with a cycle of 4 weeks on followed by 2 weeks off 25 mg IV infused over 30 to 60 minutes once weekly Gastrointestinal stromal tumor Renal cell carcinoma Renal cell carcinoma XIV. Miscellaneous antineoplastic agents 66 20H015 Hydrea Bristol 27 g/ m mg/kg/day once daily. 黑色素瘤, 慢性骨髓性白血病, 無法手術之卵巢癌, 和 as adjunctive therapy to radiation therapy of 表皮樣 (Hydroxyurea) 的頭頸癌, 減少疼痛發作和降低鐮刀型貧血輸血次 500 mg/cap 數. Dry skin (MRCC, 18% ), Rash (GIST, 14%; MRCC, 27% ), Anemia (GIST, 26%; MRCC, 71% ), Leukopenia (MRCC, 78% ), Lymphocytopenia (GIST, 38%; MRCC, 59% ), Neutropenic disorder (GIST, 53%; MRCC, 72% ), 噁心, 嘔吐常見 : Edema, Rash, Hyperglycemia, Hyperlipidemia, Hypertriglyceridemia, Hypophosphatemia, Inflammatory disease of mucous membrane, Loss of appetite, Nausea, Decreased hemoglobin, Decreased lymphocyte count, Decreased platelet count, Leukopenia, Neutropenia, Alkaline phosphatase raise, AST/SGOT level raised, Asthenia, Serum creatinine raised 骨髓抑制, 噁心, 嘔吐, 腹瀉, 便祕, 口腔粘膜炎 67 20T043 Vesanoid (Tretinoin) 10 mg/cap Roche mg/ m 2 /dayin two evenly divided, continue for 3090 days until complete remission has been achieved. Induction of remission in patients with 急性前髓性白血病. 維他命過高症狀 (CSF 壓力上升, 頭痛, 厭食, 噁心, 嘔吐, 皮膚脫屑, 疲倦, 水腫, 肝臟腫大, 脾臟腫大 ) 68 20T001 Thado (Thalidomide) 50 mg/cap 69 Temodal (Temozolomide) 20T085 (20 mg/cap) 20T069 (100 mg/cap) A075 Asadin (Arsenic trioxide) 10 mg/10 ml 10B109 Velcade (Bortezomib) 3.5 mg/vial 72 10A067 Leunase (LAsparaginase) 5000 ku/vial 東洋 Schering 東洋嬌生 1000 mg/m 2 per cycle (5day course) MAX: 60 doses 200 mg ~ 800 mg/day 肝癌, 多發性骨髓瘤嗜睡, 便祕, 皮膚紅疹, 周邊神經病變 150 mg/m 2 QD for 5 days every 4 weeks Refractory anaplastic astrocytoma 骨髓抑制, 噁心, 嘔吐, 疲倦, 頭痛, 頭暈, 運動失調, 週邊水腫. Refractory to or have relapsed from retinoid and anthracycline chemotherapy: induction, 0.15 mg/kg IV over 12 hours daily until bone marrow remission; consolidation, 0.15 mg/kg IV over 12 hours daily for 25 doses over a period up to 5 weeks; beginning 36 weeks after completing induction Intravenously (bolus) at a dose of 1.3 milligrams/ square meter twice weekly for two weeks (days 1, 4, 8, and 11). At least 3 days should elapse between consecutive doses. This is followed by a 10day rest period (day 1221); this 3week period is a treatment cycle. KYOWA 6000 International Units/m(2) IM or IV 3 times/wk; 急性前骨髓性白血病 Acute promyelocytic leukemia (APL) Multiple myeloma Mantle cell lymphoma Acute lymphoid leukemia 常見 : 噁心嘔吐腹瀉及腹痛, 呼吸困難, 白血球增多症, 疲勞水腫呼吸困難咳嗽皮疹或搔癢頭痛嚴重 : Abnormal ECG, QT prolongation, AV block, torsadedepointes, 高血糖常見 : Hypotension (11% to 12% ) Rash (18% to 21% ) Constipation (30% to 43%), Decrease in appetite (34% to 43%), Diarrhea (37%% to 57% ), Nausea (52% to 64% ), Mental disorder (35%), Fever (35% to 36% ) 嚴重 : Congestive heart failure, Heart disease (15% ), Toxic epidermal necrolysis, Vomiting (35% to 36% ), Neutropenic disorder (19% ), Thrombocytopenia (35% ) 常見 : Hyperglycemia, Abnormal liver function, Hypersensitivity reaction, Azotemia

8 73 10A136 Aflibercept (Zaltrap) 100mg/4ml SANOFIAVE NTIS XV. Imidazoquinazoline derivative agents 74 20A024 Agrylin Shire US (Anagrelide) 0.5 mg/cap 4 mg/kg IV infusion over 1 hour every 2 weeks Colorectal cancer 常見 : Hypertension, fatigue, dysphonia, headache palmarplantar erythrodysesthesia, diarrhea, stomatitis, appetite decreased, weight loss, abdominal pain, upper abdominal pain leukopenia, neutropenia, thrombocytopenia, bleeding, AST increased, ALT increased,weakness,proteinuria, creatinine increased,epistaxis, dyspnea, infection. MAX: 0.5 mg/day increase in any 1 wk XVI. Dichlorodiphenyl trichloroethane(ddt) derivative agents 75 HRA Pharma 20M078 MAX:1819 grams Lysodren ORALLY daily (Mitotane) 500 mg/tab XVII. Nitrosoureas 76 10C209 BCNU (Carmustine ) 100mg/vial Initial, 0.5 mg ORALLY 4 times daily OR 1 mg ORALLY twice daily for at least 1 wk Initial: 2 to 6 grams ORALLY daily (divided 3 to 4 times/day); maintenance: 2 to 16 grams ORALLY daily (divided 34 times/day); normal dose is 910 grams/day Thrombocytosis, Secondary to myeloproliferative disorders Adrenal carcinoma, Inoperable BRISTOL 150 to 200 mg/m(2) IV every 6 weeks Glioblastoma multiforme of brain, Recurrent; as an adjunct to surgery Hodgkin's disease, Relapsed or refractory, in combination with other approved agents Intracranial tumor, Malignant Malignant glioma Neoplasm of brain stem Malignant glioma of brain, Highgrade, newly diagnosed; adjunct to surgery and radiation Multiple myeloma, In combination with prednisone NonHodgkin's lymphoma, Relapsed or refractory, in combination with other approved agents 參考資料 :1. Micromedex Healthcare Series 藥物仿單 Abdominal pain (16.4%), Diarrhea (25.7%), Nausea (17.1%), Asthenia (23.1%), Dizziness (15.4%), Headache (43.5%), Dyspnea (11.9%), Fever (8.9%) 常見 :Rash, Diarrhea, Loss of appetite, Nausea, Vomiting, Dizziness, Lethargy, Somnolence, Vertigo 嚴重 : Hypertension, Orthostatic hypotension, Hemorrhagic cystitis 常見 : Constipation, Nausea, Vomiting, Impaired wound healing, Asthenia, Headache, Depression, Urinary tract infectious disease, Fever

12 20C044 Xeloda (Capecitabine) 500 mg/tab 13 Ara C (Cytarabine) 10C095 (100 mg1ml//vial) 10C087 (500 mg/5ml/vial) 14 20M010 M.T.X (Methotrexate) 2.5

12 20C044 Xeloda (Capecitabine) 500 mg/tab 13 Ara C (Cytarabine) 10C095 (100 mg1ml//vial) 10C087 (500 mg/5ml/vial) 14 20M010 M.T.X (Methotrexate) 2.5 No. 藥品代號 Trade name ( Generic name) (Potency) I. Alkylating Agents 1 20B021 Myleran (Busulfan) 2 mg/tab 2 20C052 Leukeran (Chlorambucil) 2 mg/tab 3 20A016 Alkeran (melphalan) 2 mg/tab 4 10M079 Alkeran